MX2021003090A - Sal de erbumina de treprostinil. - Google Patents

Sal de erbumina de treprostinil.

Info

Publication number
MX2021003090A
MX2021003090A MX2021003090A MX2021003090A MX2021003090A MX 2021003090 A MX2021003090 A MX 2021003090A MX 2021003090 A MX2021003090 A MX 2021003090A MX 2021003090 A MX2021003090 A MX 2021003090A MX 2021003090 A MX2021003090 A MX 2021003090A
Authority
MX
Mexico
Prior art keywords
treprostinil
erbumine salt
salt
erbumine
preparation
Prior art date
Application number
MX2021003090A
Other languages
English (en)
Inventor
David Michael Remick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021003090A publication Critical patent/MX2021003090A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/16—Benz[e]indenes; Hydrogenated benz[e]indenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen una nueva sal de treprostinil y métodos para su preparación y uso.
MX2021003090A 2018-09-18 2019-09-11 Sal de erbumina de treprostinil. MX2021003090A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732799P 2018-09-18 2018-09-18
PCT/US2019/050632 WO2020060823A1 (en) 2018-09-18 2019-09-11 Erbumine salt of treprostinil

Publications (1)

Publication Number Publication Date
MX2021003090A true MX2021003090A (es) 2021-05-12

Family

ID=68052002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003090A MX2021003090A (es) 2018-09-18 2019-09-11 Sal de erbumina de treprostinil.

Country Status (12)

Country Link
US (1) US20220047535A1 (es)
EP (1) EP3853200B1 (es)
JP (1) JP7194817B2 (es)
KR (1) KR102659451B1 (es)
CN (1) CN112739679B (es)
AU (1) AU2019344541B2 (es)
BR (1) BR112021002200B1 (es)
CA (1) CA3112986A1 (es)
EA (1) EA202190552A1 (es)
IL (1) IL280891A (es)
MX (1) MX2021003090A (es)
WO (1) WO2020060823A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007081A2 (en) * 2003-05-22 2005-01-27 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
JP4906514B2 (ja) 2003-12-16 2012-03-28 ユナイテッド セラピューティクス コーポレイション 腎臓機能改善のためのトレプロスチニルの用途
KR101161889B1 (ko) 2003-12-16 2012-07-02 유나이티드 쎄러퓨틱스 코포레이션 허혈성 병변의 치료 및 예방을 위한 트레프로스티닐의 용도
CN101287457B (zh) 2004-04-12 2011-11-16 联合治疗公司 Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
CN101678033A (zh) 2007-02-09 2010-03-24 联合治疗公司 用于间质性肺病和哮喘的曲前列尼治疗
FR2920772B1 (fr) 2007-09-11 2009-10-23 Servier Lab Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine
WO2009137066A1 (en) 2008-05-08 2009-11-12 United Therapeutics Corporation Treprostinil monohydrate
CA2726599C (en) 2010-12-30 2017-07-25 Alphora Research Inc. Process for treprostinil salt preparation
US10080730B2 (en) 2013-01-09 2018-09-25 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US20140275616A1 (en) 2013-03-15 2014-09-18 United Therapeutics Corporation Salts of treprostinil
CN105722812B (zh) 2013-11-13 2018-11-16 开曼化学股份有限公司 前列环素类似物的胺盐
TWI685348B (zh) 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
US20160243064A1 (en) 2015-02-21 2016-08-25 Gavis Pharmaceuticals Novel oral pharmaceutical compositions of treprostinil
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
KR20230119035A (ko) * 2016-12-05 2023-08-14 코세어 파마 인코포레이티드 트레프로스티닐 및 이의 염의 피부 및 경피 투여

Also Published As

Publication number Publication date
AU2019344541B2 (en) 2022-01-06
EP3853200A1 (en) 2021-07-28
BR112021002200B1 (pt) 2024-03-12
EP3853200B1 (en) 2024-01-24
KR102659451B1 (ko) 2024-04-23
EA202190552A1 (ru) 2021-06-18
CN112739679A (zh) 2021-04-30
AU2019344541A1 (en) 2021-03-18
BR112021002200A2 (pt) 2021-05-04
KR20210046028A (ko) 2021-04-27
WO2020060823A1 (en) 2020-03-26
CN112739679B (zh) 2024-03-12
JP2022500468A (ja) 2022-01-04
CA3112986A1 (en) 2020-03-26
US20220047535A1 (en) 2022-02-17
JP7194817B2 (ja) 2022-12-22
IL280891A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
SG10201805246XA (en) Approximated parameter adaptation
MX2022016566A (es) Composiciones que comprenden una caseina y metodos para producir las mismas.
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
IN2014CH00247A (es)
EP3847816A4 (en) SIMPLIFICATIONS OF A LINEAR INTER-COMPONENT MODEL
EP3703743A4 (en) ORAL IMMUNOTHERAPY PROCEDURES
JO3644B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
CR20210158A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
MX369506B (es) Composiciones de sales metálicas.
JOP20190163B1 (ar) منشط nrf2
EP3353149A4 (en) PROCESS FOR THE PREPARATION OF INDOLIN COMPOUNDS AND A NOVEL INDOLIN SALT
MX2019010640A (es) Formas cristalinas de acido obeticolico.
MX2021003090A (es) Sal de erbumina de treprostinil.
WO2018075598A8 (en) SYNTHESIS OF EZH2 INHIBITORS
PH12016502592A1 (en) 3'-substituted-abscisic acid derivatives
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
MX2017002609A (es) Procedimiento mejorado para la preparacion de lacosamida y su intermediario novedoso.
NZ765226A (en) Crystal form of urat1 inhibitor, and preparation method therefor
WO2018229796A3 (en) PROCESS FOR THE PREPARATION OF BETRIXABAN CHLORHYDRATE AND BETRIXABAN MALEATE SALT
EP3752181A4 (en) LEISHMANIASIS IMMUNOTHERAPY
NZ759608A (en) Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside
EP3709989A4 (en) METHOD OF ADMINISTRATION OF TOLPERISON
MX2021015198A (es) Peptidos toxicos activados artificialmente.
CA187819S (en) Bracelet